biostudies-literatureFalade-Nwulia ONCATS NIH HHSNIAID NIH HHSNHLBI NIH HHS991-993https://www.ebi.ac.uk/biostudies/studies/S-EPMC8101059biostudies-literatureUnknown35(6)Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.AIDS (London, England)Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.PMC8101059U01 AI035043R01 AI116269U01 HL146201R03 AI096918UL1 TR001881P30 AI094189Thio CLFalade-Nwulia OWolinsky SMSeaberg ECSnider AERinaldo CRWitt MDfalseOutcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.2021-01-01T00:00:00Z2021 May2025-04-04T10:16:17.263Z2025-04-04T10:16:17.263ZS-EPMC81010593358744410.1097/qad.000000000000284410.1097/QAD.0000000000002844